Wisconsin-based fusion technology company SHINE Technologies has signed a long-term supply agreement with Nucleus RadioPharma for the supply of lutetium-177, a radioisotope used in cancer treatment therapies, including those in development for the treatment of neuroendocrine tumors, prostate cancer, and other solid tumors.
Under the multiyear agreement, SHINE will provide Lu-177 to Nucleus RadioPharma’s radioligand therapy (RLT) offerings for targeted radiopharmaceutical treatments for neuroendocrine tumors and prostate cancer. According to SHINE, the partnership underscores the need for a reliable and consistent supply of Lu-177 necessary to the effectiveness of RLTs.
The partnership also ensures Nucleus will have an adequate supply of the radioisotope required for use in clinical trials as the company investigates the efficacy of targeted radiopharmaceuticals in additional cancer types.
He said it: “Nucleus launched with the goal of addressing the scarcity of radionuclides and theranostics in production, which poses major challenges for patient care and clinical trials of new radiopharmaceuticals,” said Charles S. Conroy, chief executive officer of Nucleus. “We are pleased to partner with SHINE, allowing us to utilize its dependable supply of lutetium-177 to develop highly effective treatments for cancer patients.”
Production: SHINE’s newly opened Wisconsin facility, Cassiopeia, is expected to produce up to 200,000 doses per year of medical isotopes that are often in short supply. According to SHINE, Cassiopeia is the largest facility in North America dedicated to producing non-carrier-added Lu-177.